Arbutus Biopharma (ABUS) Return on Assets (2014 - 2026)

Arbutus Biopharma (ABUS) has reported Return on Assets for 13 consecutive years, with 0.01% the latest figure, recorded in Q1 2026.

• Quarterly Return on Assets rose 1.0% year-over-year to 0.01% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 0.01% (up 1.0% YoY) and the FY2025 annual result came in at 0.02%, down 1.0% from the prior year.
• Return on Assets rose to 0.01% in Q1 2026 per ABUS's latest filing, from 0.0% in the prior quarter.
• Over the last five years, Return on Assets for ABUS reached as high as 0.01% in Q1 2026 and fell as low as 0.01% in Q1 2025.
• A 5-year average of 0.0% and a median of 0.0% in 2025 frame the typical range for Return on Assets.
• Annual changes were most pronounced in 2022 — Return on Assets changed 0 bps — and 2026, when it advanced 1 bps.
• Year by year, Return on Assets stood at 0.0% in 2022, then tumbled by 38 bps to 0.0% in 2023, then decreased by 7 bps to 0.01% in 2024, then rose by 30 bps to 0.0% in 2025, then surged by 338 bps to 0.01% in 2026.
• According to Business Quant data, Return on Assets over the past three periods registered 0.01%, 0.0%, and 0.0% for Q1 2026, Q4 2025, and Q3 2025 respectively.